Article info
PDFResearch Article
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
- ↵a 520-626-4332 DMahadevan{at}uacc.arizona.edu
- ↵b mclanasa{at}gmail.com
- ↵c cfarber{at}smgnj.com
- ↵d mpandey{at}westclinic.com
- ↵e mariawhelden{at}gmail.com
- ↵f faass{at}alxn.com
- ↵g Terrie1858{at}gmail.com
- ↵h Anjli.kukreja{at}alexion.com
- ↵i lanli8622{at}yahoo.com
- ↵j cbedrosian{at}ultragenyx.com
- ↵k x.amy.zhang{at}gmail.com
- ↵l leonard.heffner{at}emoryhealthcare.org
Citation
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Publication history
- Received May 20, 2019
- Accepted August 14, 2019
- First published August 23, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.